In acute leukemia transformed from MPDs (N ¼ 7), we examined FLT3, N-RAS and p53 gene mutations, which were frequently found in de novo acute myeloid leukemia (AML) in addition to JAK2 gene mutation. Samples of mononuclear cells were obtained from peripheral blood or bone marrow cells stored in Nagoya University. All patients gave informed consent for study in accordance with the approval of the institutional ethics committee. We examined the JAK2 mutation by reverse transcription-PCR using the following primers: JAK2F: 5 0 -AAAGGCGTACGAAGAGAAGTAGGAG-3 0 and JAK2R: 5 0 -TCACTAAGTTTGATGAAAGGAGGAT-3 0 . The amplified 416-bp fragment was subjected to sequence analysis and restriction enzyme digestion with BsaXI. Mutations of FLT3, N-RAS and p53 genes were also analyzed as previously described. 6 JAK2 mutation was found in all of the seven patients with acute leukemia from MPDs (Table 1 ) but in none of de novo AML (N ¼ 65) and acute lymphoblastic leukemia (ALL) (N ¼ 16). UPN1 to five had homogeneous JAK2 mutations, and UPN3 showed del(20)(q?), which is coincident to homozygous mutation of JAK2. No common abnormality of karyotypes was identified, but structural abnormalities were found in five of the seven patients. Sequences of p53, N-RAS and FLT3 genes were wild type in the seven patients. Clinically, no patients achieved hematological remission after chemotherapy and their survival was 3-9 months after transformation.
JAK2 mutation reportedly involves myeloid but not lymphoid lineage. Leukemia transformation usually results in AML. Furthermore, JAK2 mutation has been reported in a small percentage of myeloid malignancies but not in lymphoid ones. 7 No JAK2 V617F mutation has been found in de novo AML and ALL in our study. However, UPN3 developed acute T-lymphoblastic leukemia (T-ALL) with CD2
After several courses of combination chemotherapy for T-ALL, the leukemia phenotype was changed to an undifferentiated type with
As lymphoblastic transformation from polycythemia vera (PV) is rare, it was difficult to distinguish whether the leukemia was related to PV. Existence of JAK2 mutation in T-ALL suggests that acute leukemia from MPDs may originate at a level of multipotential stem cell.
This study suggested that JAK2 mutation is a sole but specific mutation in acute leukemia from MPDs. It is needed to investigate the molecular second hit associated with the leukemic transformation in MPDs. [1] [2] [3] [4] [5] [6] [7] [8] This is a complex technology platform for indirect DNA measurement. It is associated with inherent variability originating during preparation, amplification, and uncalibrated product detection. Nonetheless, these semiquantitative measurements of DNA quantity are used to estimate percent chimerism (%Chm). Multiplex PCR partially overcomes this limitation by using a set of simultaneously amplified STR markers, that enables computing a mean % Chm value for the sample. [2] [3] [4] [5] [6] [7] [8] This sample mean closely approximates the True chimerism level when the sample variance is low, and the platform performance can be independently determined to be optimal. 8 A critical question still remains: how do you gauge the platform performance for an individual clinical sample, and consequently, the reliability of an estimate of %Chm derived from these data?
Owing to the clinical importance of this issue, a paradigm for sample performance assessment was developed as a component of our chimerism monitoring routine. The paradigm integrates novel nonstatistical, quantitative parameters, with traditional statistical measures of performance for a multiplex platform. The
Letters to the Editor nonstatistical parameters estimate deviations from optimal platform performance for STR markers at individual loci. The purpose of this report is to describe the parameters, and to show how the paradigm allows one to immediately gauge the reliability of results for a single chimeric sample, whether mixed or complete. The %Chm, and all parameters, can be computed and displayed simultaneously, since they derive from the same DNA data.
Our laboratory's routine chimerism monitoring is performed on peripheral blood and bone marrow. The ABI AmpflSTR SGM Plus kit, which has 10 polymorphic marker-loci, and the ABI 3100 analyzer are used. Patients usually have 3-5 informative loci in a sample. For each informative locus the %Chm is estimated based on the following formula:
where A represents STR-DNA measurements for either a donor (D) or recipient (R)-derived alleles in the chimera, and B represents allelic DNA from the other source; A1, B1 are the shorter of the alleles in each pair (Recipient refers to the patient before transplantation.). The DNA measurements used are derived from peak (band) area or height as calculated by the Genescan program (ABI). From these locus measurements, sample mean %Chm, the standard deviation (s.d.) and coefficient of variation (cv ¼ s.d./mean) are computed by an Excel spreadsheet application, referred to as ChimerTrack.
7,8
The proposed parametric approach, described below, will generate numerical values that indicate a locus' performance relative to optimal levels. Any deviation from optimum, or expected, performance will be referred to below as an error. In the following sections, a description of two novel parameters, and a third that was introduced previously, 8 will be described. The descriptions will include the formulas necessary for implementation, as well as typical examples of how the parameters can be used to assess STR results on individual clinical samples. Our routine, stepwise sample assessment strategy is described afterwards.
The first parameter is referred to as the DNA measurement error (%ME). This nonstatistical parameter estimates relative deviation of DNA measurements from optimal at a single locus in a sample. This new term is preferred over the less precise: 'allelic imbalance'. It is derived from the optimal performance relationships between alleles in a chimeric locus. For instance, if the platform is performing optimally at a normal heterozygous locus, the DNA measurements for each peak (band) will be equal, as in Figure 1 . Similarly, for a chimeric locus with four alleles, under ideal performance conditions, no difference in DNA quantity will be seen within the R-allele pair or the D-pair of alleles. More formally, this implies that in regards to DNA measurements, R1 ¼ R2 and D1 ¼ D2. Consequently, the difference between (R1 þ D1) and (R2 þ D2) will be zero under optimal conditions, that is (R1 þ D1) À (R2 þ D2) ¼ 0. These relationships are valid even though we do not know the actual value for the R/D ratio. Based on the foregoing we can define the best estimate of DNA measurement error (%ME) as follows:
. a This formula implies that the error (%ME) will be large when the measurement inequality for DNA between A and B is large. An important advantage of this approach is that values for measurement error (%ME) can be easily related to the resultant changes in %Chm. Some examples of this relationship were computed from hypothetical data sets using Formulas 1 and 2 at different %Chm (Table 1 ). These results demonstrate that when the True chimerism level is 50%, then a DNA measurement error of 17% produces a 5% change in %Chm. It is important to note that this is a relative -not absolute -relationship between %ME and %Chm, so that it varies as a function of the actual chimerism level (Table 1 ). We will return to this issue of the general significance of absolute versus relative changes in %Chm in subsequent sections.
Based on the foregoing definition of the %ME parameter, it would be appropriate for evaluating the following peak configurations in chimeric loci:
Four distinct DNA peaks. Three peaks: R1 þ D1 þ shared (R2/D2). For other configurations involving shared D-R alleles, locus performance can be more indirectly estimated based on the difference between the locus' %Chm and the sample mean. This difference is referred to as the Locus Error (%LE), and has been defined using the following formula: 8 
%LE ¼ ðSample Mean À Locus valueÞ Sample Mean

Â100: ð3Þ
The locus error (%LE) is a relative value -similar to the %ME or cv -so that it will change depending on the chimerism level. In practice, a 5-10% LE is a reasonable cutoff across the typical range of %Chm values (Table 3 ). a Results computed from hypothetical data sets using Formulas 1 and 2 at different %Chm, demonstrating the relative -not absoluterelationship between %ME and %Chm.
b %ME, DNA measurement error. c Abs D%, absolute difference (D) between the True %Chm value and the error value.
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The use of %ME and %LE is illustrated in Table 2 , from our actual Excel implementation, in two typical cases with similar sample means: 39 and 40%, respectively. In patient A, the variance (s.d., cv) is low which is paralleled by the finding that %ME values are below 10% for every locus. In this case, we would consider the sample estimate of %Chm to be reliable. In contrast, for patient B, the s.d. is 7%, cv 18%, representing a level of variability much higher than our recommended cutoff of cv o10% (Table 3 ). This indicates the presence of at least one unreliable locus estimate in the sample. In this type of case, the %ME is an objective and convenient way to immediately detect such unreliable locus estimates. Examining the data for patient B, it is apparent that both the 47 and 33% values have large %ME values (i.e. 18, 26). Based on the calculations in Table 1 , these %ME values indicate that the %Chm error is unacceptably large so that the 47 and 33% should be rejected as unreliable. On the other hand, the 44%Chm estimate with a %ME of 13% is the most reliable, and likely to be closest to the True chimerism level (Table 1) . In regards to the application of %LE to these cases, Table 2 shows that locus errors are much larger for the poorly performing sample in Patient B compared to Patient A. Indeed, all the loci in this case are above our rejection level of 10% (Table 3) .
It is important to note that %ME and %LE indicate 'relative net performance errors', representing combined effects from several sources. Consequently, a locus with obvious asymmetries in D and R peak values still may exhibit an acceptable %ME, and a reliable %Chm, as long as the errors are balanced (Figure 2 ). Balanced errors occur because a decrease in D or R components have opposite effects, based on Formula 1. For example, in computing donor chimerism, a decrease in the D component results in an underestimation of the true level of donor chimerism; conversely, R reductions produce an overestimation.
8
The second novel parameter is the Detection Level (%DL), or sensitivity of a locus. Sensitivity -as commonly used in chimerism testing -indicates that a minor component of x% is theoretically detectable relative to the major component. This definition is another implication of the use of the ratio expressed in Formula 1. The range for detection of the minor component is usually 1-5%Chm. [2] [3] [4] [5] [6] [7] [8] As the term 'sensitivity' has a particular statistical implication in laboratory parlance, we use this term Detection Level (%DL) instead. It is defined as follows:
where T is the Genescan software's 'peak amplitude threshold', which is expressed in Relative Fluorescent Units and is typically set at 50-75 RFU. A is the total measured DNA (i.e. peak height(s) in RFU). When the platform is expected to be sensitive to a x% minor component, then %DL must be x%, or smaller, for a minor signal to be detected. For instance, if in a given locus A ¼ 1500 RFU, T ¼ 50 RFU, then %DL ¼ 3%. If the expected sensitivity was 5% then this is an acceptable outcome, and a 5% minor component would be detectable at that locus. However, if a higher value of %DL was found -for example 10% -then a 5% homozygous minor component will be below the system's detection threshold, and no signal will be seen. In this case, the locus is less sensitive than required, and a conclusion that there is 0% minor component is unfounded, even though no minor signal is present. On the other hand, with %DL values at or below the expected sensitivity level, a minor signal theoretically can be dected. Based on the foregoing background, our stepwise strategy for sample assessment can now be described. It is routinely used in our laboratory for assessing the quantitative performance of a STR-PCR multiplex platform on individual clinical samples. This hierarchal parametric assessment paradigm integrates the nonstatistical parameters, described above, with traditional statistical measures of performance.
The assessment begins by importing a sample's DNA measurement data (e.g. peak area in Genescan) into our spreadsheet for all informative loci. This enables simultaneous computation by the spreadsheet of %Chm, cv, %ME (measurement error), %LE (locus error), %DL (detection level), as in Table 2 . Values for most parameters are a function of the These data are derived from the implementation of these parameters, within the ChimerTrack program, 7,8 using Genescan measurements of peak area or height. Abbreviations: Loc, locus; Config, size order of alleles in locus; sh, shared R2, D2; %Chm, % chimerism; %ME, % DNA measurement error; %DL, % detection level for a 5% minor component, with peak threshold at 50 RFU; %LE, % locus error is defined with respect to the mean and is not equivalent to the s.d. (see text). 
Figure 2
Chimeric locus where both the R-peak pair (filled, right) and the D-peak pair exhibit inequalities in DNA measurement that are manifested in differences in peak height. However the %ME is only 9% so that this locus estimate is reliable, and a good approximation of True.
Letters to the Editor a. Examine %ME in applicable locus configurations b. For other configurations, delete locus %Chm; our Excel spreadsheet reaverages %Chm of remaining loci c. Examine %ME for each locus (i) Accept the locus estimate if a. If %Chm o70% and %ME p15% b. If %Chm X70% and %ME p10% (ii) If %ME 410 or 15%, respectively, delete locus %Chm; the software reaverages %Chm of remaining loci 2. For presumed 0% or 100% chimerism, based on absent minor signal, examine %DL a. Delete all loci with %DL X5% (our default) for homozygous minor component b. Delete if %DL X2.5%, for heterozygotic minor component c. To accept a value of 100% or 0%Chm, at least one locus in the sample needs to be sufficiently sensitive (e.g. %DLp5%); a report of 0% based only on absence of signal is inadequate and misleading a Not relevant for samples with a single informative locus.
